Zhou Shuhan, Xu Xiaohui, Zeng Jiangqin, Liu Zhiyi, Wang Miao, Lv Wenliang
Clinical College, Hubei University of Chinese Medicine, Wuhan 430000, China.
Evid Based Complement Alternat Med. 2021 Oct 29;2021:5518750. doi: 10.1155/2021/5518750. eCollection 2021.
Lianpu drink (LPD) is a traditional Chinese medicine (TCM) formula for the treatment of chronic gastritis (CG), and its clinical effects have been effectively verified. However, due to the complexity of the chemical composition of TCM formulas, its mechanism of action has not yet been clearly explained. Many studies have shown that the principal drugs in the TCM formula play a major therapeutic role. Therefore, in this study, the principal drugs (CR) and . (MOR) in LPD were used as the main research objects to predict the mechanism of LPD on CG. We contrasted a "compounds-targets-diseases" network and screened the putative targets of CR and MOR in LPD related to CG, respectively. Furthermore, common targets of CR and MOR related to CG were selected as candidate targets. In this study, the specific target proteins of CR, MOR, and CG were combined by protein-protein interaction (PPI) to construct a pharmacological network of "components-targets-diseases." In addition, we investigated the effects of CR and MOR on the TNF signaling pathway, which mediated the remission of CG. This study preliminarily revealed that CR and MOR play a key role in the treatment of CG. Animal experiments also showed that CR and MOR could significantly improve CG by inhibiting MKK6/38 and RIP/38 pathway.
连蒲饮（LPD）是一种用于治疗慢性胃炎（CG）的中药配方，其临床疗效已得到有效验证。然而，由于中药配方化学成分的复杂性，其作用机制尚未得到明确阐释。许多研究表明，中药配方中的主要药物起主要治疗作用。因此，在本研究中，以连蒲饮中的主要药物黄连（CR）和吴茱萸（MOR）作为主要研究对象，预测连蒲饮治疗慢性胃炎的作用机制。我们对比了一个“化合物-靶点-疾病”网络，分别筛选出连蒲饮中黄连和吴茱萸与慢性胃炎相关的潜在靶点。此外，选取黄连和吴茱萸与慢性胃炎相关的共同靶点作为候选靶点。在本研究中，通过蛋白质-蛋白质相互作用（PPI）将黄连、吴茱萸和慢性胃炎的特异性靶蛋白结合起来，构建一个“成分-靶点-疾病”的药理网络。此外，我们研究了黄连和吴茱萸对介导慢性胃炎缓解的肿瘤坏死因子（TNF）信号通路的影响。本研究初步揭示了黄连和吴茱萸在慢性胃炎治疗中起关键作用。动物实验也表明，黄连和吴茱萸可通过抑制MKK6/38和RIP/38通路显著改善慢性胃炎。
